Baumann C, Ullrich A, Torka R. GAS6-expressing and self-sustaining cancer cells in 3D spheroids activate the PDK-RSK-mTOR pathway for survival and drug resistance. Mol Oncol. 2017;11:1430-1447 pubmed 出版商

Cai W, Sakaguchi M, Kleinridders A, Gonzalez Del Pino G, Dreyfuss J, O Neill B, et al. Domain-dependent effects of insulin and IGF-1 receptors on signalling and gene expression. Nat Commun. 2017;8:14892 pubmed 出版商

Gu Y, Li H, Zhao L, Zhao S, He W, Rui L, et al. GRP78 confers the resistance to 5-FU by activating the c-Src/LSF/TS axis in hepatocellular carcinoma. Oncotarget. 2015;6:33658-74 pubmed 出版商

Yan S, Um S, Peek V, Stephens J, Zeng W, Konicek B, et al. MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping. Invest New Drugs. 2018;36:536-544 pubmed 出版商

Nakagawa T, Takeuchi S, Yamada T, Nanjo S, Ishikawa D, Sano T, et al. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. Mol Cancer Ther. 2012;11:2149-57 pubmed 出版商

Takeuchi S, Wang W, Li Q, Yamada T, Kita K, Donev I, et al. Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer. Am J Pathol. 2012;181:1034-43 pubmed 出版商

Yamada T, Takeuchi S, Nakade J, Kita K, Nakagawa T, Nanjo S, et al. Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells. Clin Cancer Res. 2012;18:3592-602 pubmed 出版商

Wang W, Li Q, Takeuchi S, Yamada T, Koizumi H, Nakamura T, et al. Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer. Clin Cancer Res. 2012;18:1663-71 pubmed 出版商